Glial progenitor cells (GPCs) comprise the most abundant population of progenitor cells in the adult human brain. They are responsible for central nervous system (CNS) remyelination, and likely contribute to the astrogliotic response to brain injury and degeneration as well. Adult human GPCs are biased to differentiate as oligodendrocytes and elaborate new myelin, and yet they retain multilineage plasticity, and can give rise to neurons as well as astrocytes and oligodendrocytes once removed from the adult parenchymal environment. GPCs retain strong mechanisms for cell-autonomous self-renewal, and yet both their phenotype and fate may be dictated by their microenvironment. Using the transcriptional profiles of acutely isolated GPCs, we have begun to understand the operative ligand-receptor interactions involved in these processes, and have identified several key signaling pathways by which adult human GPCs may be reliably instructed to either oligodendrocytic or astrocytic fate. In addition, we have noted significant differences between the expressed genes and dominant signaling pathways of fetal and adult human GPCs, as well as between rodent and human GPCs. The latter data in particular call into question therapeutic strategies predicated solely upon data obtained using rodents, while perhaps highlighting the extent to which evolution has been attended by the phylogenetic modification of glial phenotype and function.
A D U L T G L I A L P R O G E N I T O R C E L L S A R E W I D E L Y D I S T R I B U T E D T H R O U G H O U T A D U L T H U M A N B R A I N
Glial progenitor cells (GPCs) comprise the most abundant progenitor cell population of the adult mammalian brain. These cells, often described as oligodendrocyte progenitor cells, were first isolated from rodent optic nerve in the 1980s by Raff and colleagues, and were initially characterized as bipotential for both oligodendrocytes and type-2 astrocytes in culture (Raff et al., 1983; Temple and Raff, 1985; ffrench-Constant and Raff, 1986) . GPCs have since been isolated from all regions of the rodent nervous system (Hardy and Reynolds, 1991; Zhang et al., 1999) . In the developing central nervous system (CNS), GPCs -as defined by NG2 and/or PDGFaR expression -are responsible for the generation of oligodendrocytes and myelin, as well as for the generation of at least some parenchymal astrocytes (Rivers et al., 2008; Zhu et al., 2008) . In the adult brain, GPCs may be responsible for the oligodendrocyte regeneration and remyelination that follows various CNS insults (Franklin, 2002) . In addition, they may account for homeostatic turnover of both glial progenitors and some parenchymal astrocytes, as well as some aspects and phenotypes of reactive gliosis, although the latter point remains controversial (Dimou et al., 2008) .
In the human brain, GPCs were first identified histologically using antibodies against either PDGFaR or the gangliosides recognized by the A2B5 antibody (Scolding et al., 1998) ; post-mitotic pre-oligodendrocytes were then identified in cultures of human white matter, using monoclonal antibody against an oligodendrocytic sulfatide, as recognized by MAb O4 (Armstrong et al., 1992; Gogate et al., 1994) . However, while this antibody recognizes mitotic oligodendrocyte and GPCs in adult rodent tissues, it does not do so in humans, in whom its expression seems restricted to post-mitotic, oligodendroglially committed cells (Kirschenbaum et al., 1994) . Rather, mitotic GPCs were first isolated from the human subcortical white matter using CNP promoter-driven, GFP-based fluorescence-activated cell sorting (FACS) (Roy et al., 1999; Nunes et al., 2003) , and later by A2B5-directed FACS (Windrem et al., 2002; Nunes et al., 2003) . These cells proved relatively abundant, comprising between 3 and 4% of all cells within the normal adult human white matter. Importantly, although previously described in humans as white matter progenitor cells (Goldman, 2003 Q1 ), GPCs are not restricted to adult human white matter. To the contrary, we have recently established that 3.2 + 0.6% (n ¼ 14) of all cells within dissociates of adult human temporal cortical gray matter can be identified as A2B5
þ GPCs (unpublished data).
H U M A N G P C s A R E M Y E L I N O G E N I C I N V I V O
Acutely isolated human GPCs, whether enriched by A2B5 or P/CNP2:GFP-based sorting, typically differentiate as both oligodendrocytes and astrocytes Roy et al. (1999) Q2 in vitro (Roy et al., 1999; Windrem et al., 2002) . If provided a culture environment permissive for oligodendrocytic differentiation, human GPCs follow the typical program of in vitro rodent oligodendrocytic differentiation; they serially express the oligodendroglial maturation markers O4 and O1, which recognize sulfatide and galactocerebroside, respectively, and ultimately develop as morphologically mature oligodendrocytes. In vivo, isolates of adult human GPCs are highly myelinogenic, ensheathing host axons once xenografted into either the adult demyelinated or congenitally hypomyelinated rodent brain. In particular, we have found that when transplanted into lysolecithin-demyelinated callosal lesions, adult human GPCs can differentiate as CNP þ /MBP þ oligodendrocytes that can efficiently enwrap and remyelinate surviving resident axons (Windrem et al., 2002) .
Once the ability of adult human GPCs to ensheath demyelinated axons was demonstrated, their myelinogenic potential was assessed more systematically, following perinatal xenograft into the hypomyelinated shiverer mouse forebrain (Windrem et al., 2004) . The adult GPCs differentiated as MBP-expressing oligodendrocytes within 4 weeks after engraftment, and went on to achieve widespread and dense myelination by 12 weeks. On that basis, with the goal of establishing a more abundant source of potentially myelinogenic human GPCs for experimental therapeutics, we assessed the incidence and lineage competence of GPCs derived from the second trimester fetal human forebrain. We found that in contrast to their adult-derived counterparts, A2B5
þ /PSA-NCAM 2 GPCs derived from the fetal human brain took 8 weeks to generate appreciable numbers of myelinating oligodendrocytes, and at least 12 weeks to generate the same level of myelination achieved within just 4 weeks by adult GPCs (Windrem et al., 2004) . In both fetal and adult xenografts, the human donor GPCs developed as astrocytes and myelinating oligodendrocytes in a context-dependent fashion, such that those donor cells that engrafted presumptive white matter developed as oligodendrocytes, whereas those invading cortical and subcortical gray developed largely as astrocytes. Yet the majority of donor cells engrafted the white matter, so that within 3 months after a single intracerebral injection of donor GPCs into neonatal shiverer mice, whether of fetal or adult origin, the hosts typically expressed MBP throughout the entire extents of their corpus callosa and internal capsules, to and beyond the cerebral peduncles ( Fig. 1A-C) . The myelin produced by these cells was ultrastructurally normal, with the reconstitution of dense myelin characterized by major dense lines, normal G-ratios and reestablished nodal architecture (Fig. 1D) (Windrem et al., 2004; Goldman et al., 2008) ; furthermore, fetal GPCs proved capable of fully rescuing the shiverer mouse, in terms of both its survival and neurological phenotype (Fig. 1E ) .
Thus, both fetal and adult-derived human GPCs proved capable of efficient and widespread myelination of recipient unmyelinated tissues, whether hypomyelinated or demyelinated. This observation suggested the potential therapeutic utility of human GPC grafts in a variety of both pediatric and adult myelin disorders, an extensive topic that we have recently reviewed elsewhere (Keyoung and Goldman, 2007; Goldman et al., 2008 ). Yet besides the potential significance of this work to experimental therapeutics in myelin disease, these studies revealed a number of intriguing observations in regard to the cell biology of parenchymal GPCs. In particular, we noted that adult GPCs were clearly more biased towards oligodendrocyte differentiation than their fetal counterparts, as they yielded a larger proportion of oligodendrocytes, myelinated more quickly and with higher efficiency, and ensheathed greater numbers of axons per donor cell, than did fetal GPCs. This difference was not due to any deficit in the ability of fetal GPCs to myelinate the shiverer forebrain; to the contrary, despite their longer latencies to differentiation, neonatally transplanted fetal GPCs proved able to eventually myelinate the entire neuraxis, resulting in the frank rescue of otherwise-doomed shiverer homozygotes . Rather, the more rapid rate of myelination by adult GPCs suggests that these cells are more phenotypically committed than their fetal counterparts, and are primed to undergo more rapid terminal differentiation in vivo, with the more frequent assumption of oligodendrocytic fate.
Despite their nominal description as GPCs, adult glial progenitors retain the capacity to generate neurons upon removal from their tissue environment (Roy et al., 1999; Belachew et al., 2003; Nunes et al., 2003) . Roy et al. first noted that adult human GPCs generated occasional neurons once removed to low-density, high-purity culture, suggesting that once removed from autocrine and paracrine agents, the cells revealed a broader lineage capacity than previously appreciated (Roy et al., 1999) . In subsequent experiments (Nunes et al., 2003) , the authors followed up this observation by isolating adult human GPCs and raising them in lowdensity suspension culture, in which they efficiently expanded as neurospheres. These GPC-derived neurospheres generated neurons as well as astrocytes and oligodendrocytes, and could be observed to do so clonally (Nunes et al., 2003) . The neurons that differentiated from these adult GPC-derived neurospheres were largely GABAergic, and responded with both substantial calcium transients and action potentials to depolarization (Fig. 2) . Of note, when freshly isolated adult GPCs were directly xenografted into prenatal rat brain, donor cells differentiated into representatives of all three major neural lineages, including neurons; the latter were noted in the striatum, hippocampus and olfactory bulb, all areas whose local environments support late and/or postnatal neurogenesis (Nunes et al., 2003) . This Q3 observation suggested that no reprogramming events were necessary for the emergence of neurogenesis by adult human parenchymal GPCs. In parallel studies of adult rodent GPCs, NG2-defined GPCs were likewise found to be intrinsically neurogenic and multipotent (Belachew et al., 2003; He and Shen, 2009 ). Interestingly, NG2
þ cells identified as adventitial perivascular cells were similarly observed to generate neurons in the adult primate hippocampus (Yamashima et al., 2004) . In contrast to these observations with adult GPCs, the acquisition of multilineage competence by neonatally derived glial progenitors has only been reported after BMP-initiated astrocytic differentiation, followed by reprogramming in sustained culture (Kondo and Raff, 2000) . Nonetheless, other groups have reported ample numbers of multipotential progenitors in the parenchyma of both developing and adult brain that have not been otherwise isolated or explicitly identified as glial in nature (Pincus et al., 1997; Palmer et al., 1999; Arsenijevic et al., 2001; He et al., 2001 ). Yet given the largely nonquantitative nature of these studies, whether the multilineagecompetent progenitors that persist in adult brain tissue comprise minor subpopulations of multipotential cells within a much larger pool of restricted glial progenitors, or whether they instead reflect a universal, context-dependent emergence of a multipotent phenotype by GPCs once removed from their tissue environment, remains unclear. In this regard, transgenic fate-mapping studies have shown that PDGFaR-defined GPCs continue to generate neurons well into adulthood, although in vivo neurogenesis by tagged GPCs was restricted to granule neurons within the pyriform cortex (Rivers et al., 2008) .
Whether fetal and early postnatal GPCs differ from their adult counterparts in terms of their neurogenic competence is similarly unclear, as different age-defined GPCs have not yet been directly compared in a given species, under a defined set of culture conditions, in terms of their lineage potential. Nonetheless, fetal and early postnatal GPCs clearly differ from adult GPCs in a number of other cell-autonomous features. In particular, besides the greater efficiency and relative bias of adult glial progenitors towards oligodendrocytic maturation and myelination, as previously noted (Windrem et al., 127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189 fate determination of adult human glial progenitor cells2004), adult glial progenitors also differ markedly from their fetal counterparts in their slower turnover, longer cell cycle and diminished self-renewal capacity (Noble et al., 1992; Windrem et al., 2004) . These differences might be explained by differences in the chromatin structure of adult and neonatal progenitors. The GPCs of aged rodents have been reported to exhibit substantial epigenetic reprogramming, including the inactivation of histone deacetylases and re-expression of the neural progenitor markers such as sox2 (Shen et al., 2008a, b) . Interestingly, sox2 protein is also expressed by Olig2-and NG2-defined GPCs in the adult human white matter (unpublished observations), while the transcript Shows an image of WMPC-derived cells loaded with the calcium indicator dye fluo-3, 10 days after plating of first passage spheres derived from A2B5-sorted white matter (35 DIV total); many fiber-bearing cells of both neuronal and glial morphologies are apparent. (H) Same field after exposure to 100 mM glutamate, and (I) after exposure to a depolarizing stimulus of 60 mM KCl. The neurons displayed rapid, reversible, .100% elevations in cytosolic calcium in response to K þ , consistent with the activity of neuronal voltage-gated calcium channels. Scale ¼ 80 mm. (J,K) Whole cell patch-clamp revealed voltage-gated sodium currents and action potentials in WMPC-derived neurons. (J) A representative cell 14 days after plating of a first passage sphere derived from A2B5-sorted white matter. The cell was patch clamped in a voltage-clamped configuration, and its responses to current injection recorded. (K) The fast negative deflections noted after current injection are typical of the voltage-gated sodium currents of mature neurons. Action potentials were noted only at I Na . 800 pA. Modified from Nunes et al. (2003). 190 191 192 193 194 195 196 197 198 199 200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252 profile of A2B5-isolated GPCs suggests high relative expression of the undifferentiated neural progenitor transcription factors Mash1 and hes1 (Sim et al., 2006) . Together, these expression data suggest that the epigenetic state of adult GPCs, while biased to glial and especially oligodendrocytic fate, nonetheless remains permissive for multilineage differentiation.
P C s P R E D I C T S T H E I R R E S P O N S I V E N E S S T O C U E S
The signaling pathways that regulate GPC homeostasis and fate decisions in the adult human brain are not well understood. Yet since GPCs do not appear to generate neurons unless removed from their local environment, it seems evident that the adult tissue environment may actively modulate the commitment of GPCs, to prevent the expression of their latent neurogenic potential (Sim and Goldman, 2005) . Just as rodent neural progenitors lose their capacity to generate new neurons when transplanted into non-neurogenic regions (Gage, 2000; Lim et al., 2000) , GPCs may retain some competence for neuronal differentiation once provided a neurogenic niche (Nunes et al., 2003) . This responsiveness of adult human GPCs to environmental cues seems critical not only to their potential for neurogenesis, but more typically and broadly, to their ability to generate oligodendrocytes in the setting of demyelination, or perhaps astrocytes in the setting of parenchymal injury. To better understand the molecular regulation of such fate choices exhibited by adult human GPCs, we have sought to identify the major cell-cell signaling pathways specific to resident adult human GPCs, as a means of better predicting and directing their responses to both pathological and therapeutic stimuli.
To this end, we have begun to define the RNA expression patterns, and hence enabled signaling mechanisms, of A2B5-isolated adult human GPCs. We first performed expression analysis using Affymetrix U95 microarrays, by which we compared the A2B5-sorted GPC profile to the white matter tissue from which the cells derived. From three patients, we performed a pair-wise approach to identify those transcripts whose expression was significantly enriched in human GPCs (Sim et al., 2006) . Following multiple-testing correction, we identified 132 genes as significantly over-expressed in GPCs relative to their tissue environment. These included a number of cell surface receptors expressed at high levels along with their cognate ligands, suggesting the presence of several active autocrine signaling pathways in GPCs. We confirmed the functional importance of two of these pathways, the perturbation of which induced either oligodendrocytic or astrocytic commitment under conditions otherwise permissive for selfrenewing division. The first of these was represented by the receptor tyrosine phosphatase PTPRZ1, whose only known ligand pleiotrophin (PTN), was also highly expressed, along with PTPRZ1's in cis binding partners, tenascin R, NrCAM and the chondroitin sulfate proteoglycans. Importantly, the phosphatase domain of PTPRZ1 has been shown to target b-catenin for tyrosine dephosphorylation and sequestration at the plasma membrane by cadherin (Meng et al., 2000) . On this basis, we predicted that the inhibition of PTPRZ1 might interfere with canonical WNT signaling through b-catenin, and thereby abrogate GPC self-renewal. We thus challenged this pathway with both bpV(Phen), an oxovanadate inhibitor of receptor tyrosine phosphatases, and a specific lentiviral shRNAi directed against the chondroitin sulfate binding region of PTPRZ1. We found that treatment of GPCs with bpV(phen) induced a dose-dependent induction of O4-defined oligodendrocytic commitment, just as infection with lenti-PTPRZ1 shRNAi resulted in the similar induction of oligodendrocyte differentiation; together, these data indicated that the differentiative effect of bpV(phen) accrued to the inhibition of PTPRZ1 (Fig. 3) .
Besides the PTPRZ1 pathway, we also identified BMP signaling as an important regulator of human GPC self-renewal. Active BMP signaling can promote the differentiation of neural progenitors towards an astrocytic fate, and in so doing inhibit both neurogenesis and oligodendroglial differentiation (Gross et al., 1996) . Adult human GPCs expressed high levels of the BMP antagonists BAMBI, a dominant negative BMP receptor 1-like protein, and neuralin/CHRDL1, a secreted BMP antagonist similar to chordin (Sim et al., 2006) . This suggested that GPCs might effectively protect themselves from BMP signaling, by a two-tiered strategy of cell-autonomous BMP inhibition, thereby permitting their undifferentiated selfmaintenance. On that basis, we tested the effects of BMP signaling upon isolated GPCs. We found that BMP4 (5 ng/ml) -but not the related ligands BMP-2 and BMP-7, induced rapid acquisition of astrocytic phenotype, confirmed by high level GFAP-expression by 7 days in vitro (Fig. 3) (Sim et al., 2006) . In contrast, this process of BMP-induced astrocyte commitment could be blocked by exogenous noggin, a broad-spectrum BMP antagonist. Indeed, noggin-treatment encouraged the selfrenewing expansion of adult human GPCs, consistent with the active secretion of BMP ligands by these cells. These data suggest that adult human GPCs in vivo may actively prevent their own differentiation, which may rather be induced by local injury or disease, or by removal to a niche permissive for terminal differentiation (Nunes et al., 2003) . Together, these observations suggest the active cell-autonomous support of selfrenewal by GPCs in the adult human white matter parenchyma.
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To more precisely determine the molecular phenotype of human GPCs, we extended our genomics analyses of A2B5-sorted human GPCs. We isolated adult GPCs from matched white and gray matter dissociates of temporal lobes taken from four patients with medication-refractory epilepsy, using A2B5-based magnetic cell sorting as previously described (Sim et al., 2006) (ages 30-46 years). RNA was extracted from A2B5-sorted cells and their corresponding unsorted white and gray matter dissociates and then analyzed using Affymetrix U133 þ 2 arrays. This platform interrogated .20,000 genes, more than three times the number of genes represented in our initial analysis using U95 arrays (Sim et al., 2006) . To better define those transcripts specifically regulated in GPCs, we also isolated and profiled the expressed transcripts of CD11b þ microglia (n ¼ 4, ages 9-53 years), and GLT1 þ astrocytes (n ¼ 3, ages 9-19 years), using MACS followed by microarray analysis. RNA was also profiled from the matched GLT1 2 fraction as a control pool. These arrays formed a large data set that 253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315 fate determination of adult human glial progenitor cellsincluded 24 arrays from seven distinct cell populations. Briefly, raw data were preprocessed and normalized using the RMA approach (Irizarry et al., 2003) , and non-informative data were removed as described (Talloen et al., 2007) . Our initial analyses, which included principal component analysis and hierarchical clustering, illustrated clear distinctions between the GPC (A2B5), astrocyte (GLT1) and microglial (CD11b) expression profiles (Fig. 4A,B) . In addition, the expression levels of a broad panel of cell type-selective marker genes validated the specificity of our cell isolation strategies (Fig. 4C) . We found that the A2B5-sorted GPCs expressed very high and significant levels, relative to unsorted cells, of the prototypic GPC transcripts PDGFaR (PDGFRA, 12-fold higher than unsorted cells, false-discovery rate (FDR)-corrected q-value ¼ 4.7 Â 10 28 ) and NG2 (CSPG4, 7.2-fold, q ¼ 2.0 Â 10 27 ), as well as the enzyme responsible for A2B5 synthesis, GD3 synthase (ST8SIA1, six-fold, q ¼ 4.2 Â 10 28 ). In contrast, CD11b þ microglial cells expressed very low levels of these GPC-markers, but high levels of RNAs encoding the microglial proteins CD36, CD68, CD86 and FcR, as well as CD11b itself (each .three-fold higher than in unsorted cells). Similarly, astrocytes isolated on the basis of GLT1-immunoreactivity exhibited high level expression of the astrocytic transcripts AQP4, GFAP, glutamine synthase (GLUL) and GLT1 (SLC1A2) (each .five-fold higher than in controls).
Once we had developed these data sets, we performed differential gene expression analysis to quantify the differences in gene expression between these populations. Using a Bayesian linear model approach (Smyth, 2004) , we compared A2B5 þ GPCs, GLT1 þ astrocytes and CD11b þ microglia to unsorted dissociates of white and gray matter from agematched patients. Statistically significant differences were assessed following multiple testing correction using a 5% false discovery rate, and only those genes expressed at levels .three-fold relative to unsorted cells were identified as enriched in the cell type of interest (Fig. 4D) . We next defined GPC-specific genes as those genes that were significantly expressed in A2B5 þ GPCs, but not over-expressed in either the GLT1 þ or CD11b þ populations. By this means, we identified .300 genes as specifically expressed by adult human GPCs, relative to both astrocytes and microglial cells, as well as to their unsorted dissociates. As expected, these included the known GPC markers, PDGFRA, CSPG4 and ST8SIA1. Indeed, overall our U95 and U133 þ 2 data sets were highly homologous (Fig. 5A) .
H U M A N G P C s A R E M O L E C U L A R L Y D I S T I N C T F R O M T H E I R M O U S E O P C H O M O L O G S
To assess the potential differences between human and mouse GPCs, we next compared the U133 þ 2 based profile of A2B5 þ GPCs to that of mouse GPCs, using a previously published profile (Cahoy et al., 2008) . Of the 894 genes defined as significantly expressed by mouse GPCs (.five-fold change; see Supplemental Table 17 of Cahoy et al., 2008) , human homologues were found for 691; 557 of these were represented in the human profiles. A simple statistical comparison of these genes with human GPC-enriched genes suggested a significant overlap (Fisher's exact test, p , 1 Â 10 
215
). Nonetheless, the profiles of mouse GPCs were substantially different from human GPCs (Fig. 5B,C) . The importance of species differences in GPCs has been recently exemplified by Hu and colleagues (Hu et al., 2009) , who determined that whereas FGF2 signaling permits the expansion of rodent GPCs, it rather prevents acquisition of the GPC phenotype by human ES-derived neuroepithelial cells. Similarly, Nedergaard and colleagues recently reported substantial differences in the morphological phenotypes of rodent and human astroglia (Oberheim et al., 2006 (Oberheim et al., , 2009 , and have recently identified significant differences in their respective molecular signatures and dominant signaling pathways as well (unpublished). Thus, the signaling pathways that regulate human GPCs cannot be assumed to be identical to those of rodent cells; these data suggest that pharmacological data acquired using rodent GPCs cannot be readily -or even safely -extrapolated to the modulation of human GPCs, whether for purposes of induced remyelination or astroglial suppression. These data suggest that for preclinical modeling, human GPCs should best be evaluated directly, both in vitro and after xenograft in vivo, lest inappropriate mechanistic conclusions be drawn from the molecular analysis of rodent GPCs.
G E N E S E T E N R I C H M E N T A N A L Y S I S I D E N T I F I E D A G P C F A T E -R E G U L A T I N G S T E R O L H O M E O S T A S I S P A T H W A Y
To better define the differentially activated pathways of adult human GPCs, we used our U133 þ 2 human GPC transcriptome data set as the basis for gene set enrichment analysis (GSEA) against a number of available pathway databases (PGSEA, Bioconductor). GSEA allows for the identification of relevant pathways whose constituents are significantly Fig. 4 . Whole transcriptome analysis of adult human glial progenitors. Adult human glial progenitors were isolated from patients with medically refractory epilepsies, using immunomagnetic cell sorting (MACS) based on A2B5-immunoreactivity. The Affymetrix U133 þ 2 microarray expression profiles of these A2B5 þ GPCs were then compared to profiles generated from matched unsorted white and gray matter dissociates, as well as to the profiles of GLT1-sorted astrocytes and CD11b-sorted microglial cells. Initial exploratory data analysis employed both principal component analysis (A) and hierarchical clustering of the Euclidean distances (B) between samples of informative probe sets, from RMA-normalized data. Clear distinctions between each cell population were noted. (C) The expression of cell type-specific marker genes illustrates the relative enrichment of GPC, microglial and astrocytic genes, in A2B5, CD11b and GLT sorted cells, respectively (heatmap: red ¼ high expression; green ¼ lower expression). (D) Differential gene expression was performed using linear modeling, as an empirical Bayes test statistic with .three-fold change and 5% FDR cut-offs. The gene expression of each cell type was compared to that of the tissue dissociate from which it derived. The number of individual differentially expressed probe sets are shown in the Venn diagram. Although there is some overlap of A2B5 þ GPC and GLT1 þ astrocyte profiles, the three cell populations are clearly distinct from one another. 379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441 fate determination of adult human glial progenitor cellsover or under expressed in a given gene expression data set. Unlike per-gene expression analysis, GSEA identifies pathways on the basis of the consensus expression of all pathway components, and as such is a more sensitive means by which to predict the activity of entire molecular signaling pathways. We found that GSEA using the Biocarta database identified three pathways from the 254 Biocarta gene set database (www.biocarta.com), which were both significantly enriched in A2B5 þ GPCs relative to unsorted cells, and not enriched in either astrocytic or microglial comparisons (FDR adjusted q , 0.05, Fig. 6A ). Remarkably, we noted that the most significantly differentially expressed of these was the lipid synthesis control pathway, as regulated by sterolresponse element binding transcription factors (SREBPs) (q ¼ 0.009). Expression analysis of each pathway component revealed that several members of this pathway were specifically expressed in GPCs (Fig. 6B) . Indeed, these overexpressed components formed a coherent pathway that appeared differentially active in A2B5 þ GPCs (Fig. 6C ): The mRNA for 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the rate limiting enzyme in cholesterol synthesis, was the most upstream member of this pathway, and was significantly enriched in GPCs; this was confirmed by real-time RT-PCR (Sim et al., 2008) . Importantly, intracellular cholesterol regulates the activity of SREBPs via the sterol-sensing proteins INSIG and SCAP (Rawson, 2003) ; while these were not over-expressed at the transcript level, their gene products were present in human GPCs. Furthermore, the SREBP-activating proteolytic enzymes S1P (MBTPS1) and S2P (MBTPS2) were both highly enriched in GPCs. Together, these observations suggested that the sterol pathway is primed to become active whenever intracellular cholesterol levels decline. The down-stream transcriptional targets of SREBP were variably expressed, but most notably, the SREBP-regulated transcription factor PPARg was almost completely absent in adult GPCs. PPARg has long been shown to potentiate terminal phenotypic differentiation in a number of developmental systems, including oligodendrocyte differentiation by rodent GPCs (Saluja et al., 2001) . On this basis, we hypothesized that PPARg suppression might be integral to the maintenance of mitotically competent human glial progenitors. As such, we predicted that inhibition of HMGCR, by triggering PPARg expression, might thereby induce terminal differentiation from human GPCs.
S T A T I N T R E A T M E N T I N D U C E S O L I G O D E N D R O C Y T E D I F F E R E N T I A T I O N I N G P C s
To assess the role of HMGCR-dependent regulation of PPARg in the fate determination of human GPCs, we next challenged adult human GPCs with statins, a class of drugs that are potent inhibitors of HMGCR. Using either simvastatin or pravastatin to block the activity of HMG-CoA reductase, we found that their inhibition of cholesterol synthesis induced oligodendrocytic differentiation (Sim et al., 2008) . This effect was dose-dependent, and was mediated by the reduction in intracellular cholesterol, since media supplementation with the downstream cholesterol precursor mevalonate abrogated the effect of statin treatment. As predicted by our genomic model, oligodendrocytic differentiation was accompanied by an induction of the mRNA encoding PPARg (Inoue et al., 2000) . Application of a PPARg-specific antagonist, GW9662, blocked GPC differentiation induced by statin treatment, consistent with the necessity of PPARg signaling to statin-mediated differentiation. Importantly, statin treatment of fetal human-derived GPCs exerts a similar effect; statin-treated fetal GPCs stop dividing and differentiate, but eventually succumb to premature death in Fig. 5 . The gene expression patterns of human and mouse adult GPCs differ significantly. (A) Receiver Operating Characteristic (ROC) curve analysis was used to compare the original U95 array format-based analysis of human GPCs against the current U133 þ 2 profiles. Raw probe set data were annotated to provide unique gene identifiers, and then ranked according to the significance of differential gene expression in human A2B5
þ cells relative to unsorted white and gray matter dissociates (U133 þ 2 data, x-axis). The black line starting at the origin represents whether or not each mtaching gene was deemed significant in the U95 analysis (Sim et al., 2006) , moving up one position if significant and to right if not significant. The red line indicates the line of no discrimination, representing random gene selection. A perfect predictor of significance of the U95-derived gene list in the U133 þ 2 data set would be represented as an inverted 'L' shape. the upward deflection of the line thus indicates the exent of overlap between the two profiles. This is quantified as area under the curve (AUC) and partial AUC at 20% FDR (pAUC). The high values for both indicates that the U95 data closely agree with the U133 data, even at high specificity. (B,C) Comparison of human and mouse GPC transcript profiles. (B) Venn analysis of the overlap of human (U133) and mouse (Barres) GPC-specific genes. A total of 557 unique human homologs of mouse GPC-specific genes were found in the human array data. While 92 of these were significantly diffeerntially expressed by human A2B5
þ GPCs, another group of over 200 genes were significantly expressed in human GPCs, yet not detectable in mouse cells. (C) ROC analysis comparing the human and mouse profiles revealed that the mouse GPC profile was distinct from their human counterpart. At 20% FDR (dashed line), the human U95 genelist is .80% sensitive (green line) whereas the mouse profile showed only approximately 50% sensitivity (black line). This suggested that while the mouse GPC profiles generally resembled those of human GPCs, there were nonetheless abundant substantive differences between the two, with ample evidence of species-specific gene expression in both mouse and human GPCs.
vitro (Miron et al., 2007) . Antel and colleagues proposed an alternate pathway for statin action on human GPCs, via a perturbation of isoprenoid-dependent signaling, which can be mimicked by treatment with the ROCK inhibitors H1152 or Y-27632 (Miron et al., 2007) .
Interestingly, statins have been proposed as possible therapeutic agents for treatment of multiple sclerosis (MS) (Stanislaus et al., 1999; Bradbury, 2002) , and have been used in trials of MS patients (Vollmer et al., 2004) , based on their presumed immunomodulatory effects (Weber et al., 2005) . However, since statins have direct differentiative effects on GPCs, chronic statin treatment may risk depleting the parenchyma of functionally competent progenitors, and hence ultimately delimit myelin repair; such progenitor depletion might serve to broadly diminish the cellular plasticity of the adult brain. Indeed, recent studies examining the effect of statins in the cuprizone model of demyelination concluded that statin therapy actually reduced remyelination following cuprizone treatment (Klopfleisch et al., 2008; Miron et al., 2009) . Although the role of statin treatment in this example of impaired remyelination remains unclear, the appearance of such toxicity serves to highlight the need for understanding the signaling pathways utilized by both adult GPCs and their glial progeny, and specifically those of human origin, as a necessary antecedent to their pharmacotherapeutic targeting.
C O N C L U S I O N S
These studies have revealed that GPCs comprise an abundant population of mitotically competent, myelinogenic cells that persist within both the gray and white matter compartments of the adult human brain. These cells may contribute to remyelination in a variety of myelin pathologies, yet retain the capacity for multilineage commitment and may contribute to reactive gliosis. The local environment of adult GPC appears key to their fate determination, in that perturbations of the extracellular matrix and growth factor milieu can profoundly influence their proliferation and differentiated phenotypes. Using microarray technology, we have begun to describe the operative receptors and signaling pathways that underlie both the homeostatic self-renewal and fate choices of adult GPCs. Our initial studies identified both the BMP and PTPRZ1 pathways as key regulators of GPC fate. In this article, we have defined a more detailed profile of cell type-specific gene expression by adult human GPCs, in part by comparison to the expression profiles of both human microglia and astrocytes. Our new analysis has confirmed the importance of the sterol synthesis pathway as one such key regulatory pathway. Inhibition of cholesterol synthesis via statin treatment induced PPARg-dependent oligodendrocytic differentiation in vitro; however, this was associated with a marked reduction in Fig. 6 . Gene set enrichment analysis identifies the sterol synthesis pathway as especially prominent in adult human GPCs. Pathway analysis was performed using the Biocarta database of curated cell-cell signaling pathways (www.Biocarta.com). Gene set enrichment was calculated using parametric analysis of enrichment (Kim and Volsky, 2005) and significance assessed using a linear modeling approach. Following false discovery rate calculation, three of 254 pathways were deemed significantly enriched in human A2B5
þ GPCs relative to their dissociate and not enriched in either GLT1 þ astrocytes or CD11b þ microglial cells (5% FDR) (A). The most significant pathway at less than 1% FDR, SREBP control of lipid synthesis, was combined with additional manually annotated constituents. The expression values of each gene were summarized as a heatmap (B). Only data from the most variable probe set are shown following removal of non-informative probes. The genes were then assembled into a schematic pathway to illustrate the potential regulation of human GPCs by statin, and other inhibitors (C). Gene nodes in the pathway are colored according to expression in adult GPCs relative to the unsorted dissociate. Although the magnitude of gene expression of individual components was not extreme, the concerted over-expression of such a large number of enzymes in a single pathway indicates that this sterol synthesis pathway is likely highly active in adult GPCs.   505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567 fate determination of adult human glial progenitor cellscompetent cycling progenitors, suggesting the need for caution in the use of statins in patients with demyelinating disorders. Furthermore, our analyses revealed that while mouse GPCs resemble their human counterparts at the transcriptional level, there are substantial differences between human and mouse GPCs in the detailed compositions of their respective dominant signaling pathways. As such, the direct extrapolation from mouse to human models of targetbased drug discovery efforts must be viewed with caution; in this regard, we believe that a more rigorous identification of specific molecular targets in human GPCs, and their functional validation in human cell systems, may ultimately hasten the progress of drug discovery in both the childhood and adult disorders of myelin.
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